| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
DOI: 10.1016/j.ctrv.2012.01.001
Summary: Overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in metastatic breast cancer. While the introduction of HER2-targeted therapies, such as the mon...
|
Ahmad Awada,
Ivana Bozovic-Spasojevic,
Louis Chow
|
Review article
(In Press Corrected Proof)
|
06 February 2012 |
|
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit
DOI: 10.1016/j.ctrv.2011.12.009
Abstract: Multiple targeted agents are now available for the treatment of patients with metastatic renal cell carcinoma (mRCC). Although targeted agents offer improvements over previous treatments and...
|
Stéphane Oudard,
Reza-Thierry Elaidi
|
Review article
(In Press Corrected Proof)
|
30 January 2012 |
|
Treatment of elderly patients with glioblastoma: From clinical evidence to molecular highlights
DOI: 10.1016/j.ctrv.2011.12.010
Abstract: Elderly patients with glioblastoma are characterized by a high rate of associated morbidities, and a poor prognosis. Therefore, they have been excluded from most prospective clinical trials....
|
Cyrus Chargari,
Loïc Feuvret,
Olivier Bauduceau,
Damien Ricard,
Xavier Cuenca,
Jean-Yves Delattre,
Jean-Jacques Mazeron
et al.
|
Review article
(In Press Corrected Proof)
|
30 January 2012 |
|
Uveal melanoma
DOI: 10.1016/j.ctrv.2012.01.002
Abstract: Uveal melanoma, which arises from melanocytes residing in the stroma, is the most common primary intraocular tumor in adults. Up to 50% of patients with primary uveal melanoma will ultimatel...
|
Francesco Spagnolo,
Graziano Caltabiano,
Paola Queirolo
|
Review article
(In Press Corrected Proof)
|
24 January 2012 |
|
A preclinical and clinical review of aflibercept for the management of cancer
DOI: 10.1016/j.ctrv.2011.12.008
Abstract: Aflibercept, also known as vascular endothelial growth factor (VEGF)–Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only al...
|
Andrew Gaya,
Vivien Tse
|
Review article
(In Press Corrected Proof)
|
24 January 2012 |
|
State-of-the-art classification and multimodality treatment of malignant thymoma
DOI: 10.1016/j.ctrv.2011.11.010
Abstract: Thymomas are the most common tumors of the anterior mediastinum. Classification, treatment options and understanding of the pathophysiology of thymoma have changed over the past years. It is...
|
Hannah Koppitz,
Jürgen K. Rockstroh,
Heinrich Schüller,
Jens Standop,
Dirk Skowasch,
Hans Konrad Müller-Hermelink,
Ingo G.H. Schmidt-Wolf
et al.
|
Review article
(In Press Corrected Proof)
|
16 January 2012 |
|
Impact of bortezomib on bone health in myeloma: A review of current evidence
DOI: 10.1016/j.ctrv.2011.12.007
Abstract: Bone disease is a key feature in multiple myeloma (MM) and can have a substantial impact on patient morbidity and quality-of-life. The pathogenesis of lytic bone disease in MM is complex and...
|
Maurizio Zangari,
Evangelos Terpos,
Fenghuang Zhan,
Guido Tricot
|
Review article
(In Press Corrected Proof)
|
09 January 2012 |
|
Adjuvant immunotherapy for non-small cell lung cancer
DOI: 10.1016/j.ctrv.2011.11.008
Abstract: Non-small cell lung cancer (NSCLC) is the biggest cancer killer in the United States and worldwide. In 2011, there are estimated to be 221,130 new cases of lung cancer in the United States. ...
|
Zachary C.G. Tucker,
Benjamin A. Laguna,
Edmund Moon,
Sunil Singhal
|
Review article
(In Press Corrected Proof)
|
09 January 2012 |
|
Phenotyping drug disposition in oncology
DOI: 10.1016/j.ctrv.2011.12.003
Abstract: Efficacy and toxicity of anticancer agents are highly variable between patients and variation in drug disposition is thought to be an important determinant. Genetics, physiology, and environ...
|
Frans L. Opdam,
Hans Gelderblom,
Henk-Jan Guchelaar
|
Review article
(In Press Corrected Proof)
|
06 January 2012 |
|
Systemic treatment of advanced pancreatic cancer
DOI: 10.1016/j.ctrv.2011.12.004
Abstract: Pancreatic cancer belongs to the most malignant gastrointestinal cancers and, in its advanced stage, remains a deadly disease for nearly all affected patients. Treatment of metastatic adenoc...
|
Volker Heinemann,
Michael Haas,
Stefan Boeck
|
Review article
(In Press Corrected Proof)
|
06 January 2012 |
|
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor
DOI: 10.1016/j.ctrv.2011.12.005
Abstract: Radioimmunotherapy (RIT) is a therapeutic modality which delivers alpha, beta or Auger emitters directly to targeted cancer cells. It has the advantage of regressing tumors while reducing no...
|
Chen-Yu Huang,
Mohammad H. Pourgholami,
Barry J. Allen
|
Review article
(In Press Corrected Proof)
|
06 January 2012 |
|
Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges
DOI: 10.1016/j.ctrv.2011.12.006
Abstract: Maintenance treatment has been intensively investigated in the field of advanced/metastatic non-small lung cancer in order to improve outcomes in this devastating disease. Two different appr...
|
Athanasios G. Pallis,
Kostas Syrigos
|
Review article
(In Press Corrected Proof)
|
04 January 2012 |
|
Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade
DOI: 10.1016/j.ctrv.2011.12.001
Abstract: Introduction: The comparison of clinical cancer research characteristics across the Atlantic and their evolution over time have not been studied to date. Methods: We collected oral presentat...
|
George Pentheroudakis,
Dimitrios Krikelis,
Andres Cervantes,
Jan Vermorken,
Nicholas Pavlidis
et al.
|
Review article
(In Press Corrected Proof)
|
03 January 2012 |
|
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
DOI: 10.1016/j.ctrv.2011.11.009
Abstract: The treatment of ovarian cancer remains challenging as the majority of patients will relapse and die from their disease despite successful first-line treatment. New treatment strategies are ...
|
Fharat A. Raja,
Jane M. Hook,
Jonathan A. Ledermann
|
Review article
(In Press Corrected Proof)
|
30 December 2011 |
|
Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy
DOI: 10.1016/j.ctrv.2011.11.003
Abstract: In recent years there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the discovery of m...
|
Pek Keng Koh,
Corinne Faivre-Finn,
Fiona H. Blackhall,
Dirk De Ruysscher
|
Review article
(In Press Corrected Proof)
|
26 December 2011 |
|
Cancer stem cells hypothesis and stem cells in head and neck cancers
DOI: 10.1016/j.ctrv.2011.11.007
Summary: There is increasing evidence that the growth and spread of cancer is driven by a small subpopulation of cancer cells, defined as cancer stem cells (CSCs). Recent data indicate that the initia...
|
Giuditta Mannelli,
Oreste Gallo
|
Review article
(In Press Corrected Proof)
|
26 December 2011 |
|
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
DOI: 10.1016/j.ctrv.2011.11.005
Abstract: The last decade has brought a breakthrough in the knowledge of the biology of breast cancer. The technological development, and in particular the high throughput technologies, have allowed r...
|
Pilar Eroles,
Ana Bosch,
J. Alejandro Pérez-Fidalgo,
Ana Lluch
|
Review article
(In Press Corrected Proof)
|
19 December 2011 |
|
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
DOI: 10.1016/j.ctrv.2011.11.006
Abstract: Background: Treatment decisions in recurrent breast cancer are usually based on the estrogen (ER), progesterone (PgR) and HER2 receptor status of the primary tumour. Retrospective studies su...
|
Eitan Amir,
Mark Clemons,
Colin A. Purdie,
Naomi Miller,
Phil Quinlan,
William Geddie,
Robert E. Coleman,
Orit C. Freedman,
Lee B. Jordan,
Alastair M. Thompson
et al.
|
Review article
(In Press Corrected Proof)
|
19 December 2011 |
|
Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: Trans-arterial radio-embolisation of HCC
DOI: 10.1016/j.ctrv.2011.11.004
Abstract: Traditional radiotherapy is only effective in treating hepatocellular cancer (HCC) in doses above 50Gy, but this is above the recommended liver radiation exposure of about 35Gy, which is an ...
|
Lorenzo Andreana,
Graziella Isgrò,
Laura Marelli,
Neil Davies,
Dominic Yu,
Shaunak Navalkissoor,
Andrew K. Burroughs
et al.
|
Review article
(In Press Corrected Proof)
|
15 December 2011 |
|
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
DOI: 10.1016/j.ctrv.2011.10.008
Abstract: Background: Paclitaxel is commonly given as a 3-h infusion every 3weeks for a variety of malignancies. Several randomized clinical trials comparing weekly paclitaxel with Q3-week (Q3W) have ...
|
Ta-Chen Huang,
Toby C. Campbell
|
Review article
(In Press Corrected Proof)
|
12 December 2011 |
|
Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact
DOI: 10.1016/j.ctrv.2011.11.001
Abstract: Epithelial–mesenchymal transition (EMT) is defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. In this process, cells acquire molecular alterati...
|
Chiara Foroni,
Massimo Broggini,
Daniele Generali,
Giovanna Damia
|
Review article
(In Press Corrected Proof)
|
28 November 2011 |
|
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
DOI: 10.1016/j.ctrv.2011.11.002
Abstract: Background: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have reported conflicting results. Methods: A syst...
|
Claire L. Vale,
Jayne F. Tierney,
David Fisher,
Richard A. Adams,
Richard Kaplan,
Timothy S. Maughan,
Mahesh K.B. Parmar,
Angela M. Meade
et al.
|
Review article
(In Press Corrected Proof)
|
28 November 2011 |
|
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
DOI: 10.1016/j.ctrv.2011.10.003
Abstract: Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase have been termed ‘oncogene addicted’ to reflect their depende...
|
Jean-Charles Soria,
Tony S. Mok,
Federico Cappuzzo,
Pasi A. Jänne
|
Review article
(In Press Corrected Proof)
|
28 November 2011 |
|
Breast reconstruction: à la carte not table d’hote
DOI: 10.1016/j.ctrv.2011.10.009
Abstract: NICE guidelines emphasise the need for breast cancer patients undergoing mastectomy to be offered all appropriate options for immediate reconstruction. In the majority of hospitals this is n...
|
Ian S. Fentiman,
Jian Farhadi
|
Review article
(In Press Corrected Proof)
|
24 November 2011 |
|
Radiotherapy versus surgery within multimodality protocols for esophageal cancer – A meta-analysis of the randomized trials
DOI: 10.1016/j.ctrv.2011.10.005
Abstract: During recent years, the curative potential of radiotherapy versus surgery for esophageal cancer was investigated in randomized trials. A PubMED®, Medline®, and Web of Science® search identi...
|
Christoph Pöttgen,
Martin Stuschke
|
Review article
(In Press Corrected Proof)
|
24 November 2011 |
|
Recommendations for the optimal management of early and advanced urothelial carcinoma
DOI: 10.1016/j.ctrv.2011.10.004
Abstract: The field of urothelial carcinoma has shown considerable advances in terms of diagnosis, staging, and treatment. The increasing knowledge of molecular pathways and genes involved in the occu...
|
Daniel Castellano,
Joan Carles,
Emilio Esteban,
José Manuel Trigo,
Miguel Ángel Climent,
José Pablo Maroto,
Xavier García del Muro,
Albert Font,
Luis Paz-Ares,
José Ángel Arranz,
Joaquim Bellmunt
et al.
|
Review article
(In Press Corrected Proof)
|
24 November 2011 |
|
Emerging therapies for urothelial cancer
DOI: 10.1016/j.ctrv.2011.10.007
Abstract: Urothelial carcinoma is one of the leading causes of death in Europe and the United States. Despite its chemosensitivity, median overall survival for advanced disease is still nearly 1year. ...
|
César Serrano,
Rafael Morales,
Cristina Suárez,
Isaac Núñez,
Claudia Valverde,
Jordi Rodón,
Jordi Humbert,
Olga Padrós,
Joan Carles
et al.
|
Review article
(In Press Corrected Proof)
|
23 November 2011 |
|
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
DOI: 10.1016/j.ctrv.2011.09.004
Summary: Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequen...
|
J.M. Baas,
L.L. Krens,
H.-J. Guchelaar,
J. Ouwerkerk,
F.A de Jong,
A.P.M. Lavrijsen,
H. Gelderblom
et al.
|
Review article
(In Press Corrected Proof)
|
21 November 2011 |
|
Diffuse malignant peritoneal mesothelioma – An update on treatment
DOI: 10.1016/j.ctrv.2011.10.006
Abstract: Mesotheliomas are aggressive and lethal neoplasms arising from mesothelial cells lining the pleura, peritoneum, tunica vaginalis testis and pericardium. Malignant peritoneal mesothelioma acc...
|
Peyman Mirarabshahii,
Krishna Pillai,
Terence C. Chua,
Mohammad H. Pourgholami,
David L. Morris
et al.
|
Review article
(In Press Corrected Proof)
|
21 November 2011 |
|
Options on fertility preservation in female cancer patients
DOI: 10.1016/j.ctrv.2011.10.002
Abstract: Infertility following treatment of cancer is a quality of survival’s recognized issue and efforts should be made to help young cancer patients retaining their fertility potential. Options to...
|
Kenny A. Rodriguez-Wallberg,
Kutluk Oktay
|
Review article
(In Press Corrected Proof)
|
11 November 2011 |
|
Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance
DOI: 10.1016/j.ctrv.2011.10.001
Abstract: The use of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumors (GIST). Currently, imatinib mesy...
|
Shreyaskumar Patel
|
Review article
(In Press Corrected Proof)
|
31 October 2011 |
|
Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications
DOI: 10.1016/j.ctrv.2011.09.002
Abstract: In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the cli...
|
Aspasia Soultati,
Giannis Mountzios,
Chrysoula Avgerinou,
George Papaxoinis,
Dimitrios Pectasides,
Meletios-Athanassios Dimopoulos,
Christos Papadimitriou
et al.
|
Review article
(In Press Corrected Proof)
|
10 October 2011 |
|
Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature
DOI: 10.1016/j.ctrv.2011.09.003
Abstract: The bone marrow microenvironment provides a site for cancer cells to evade systemic anticancer therapy. Dormant tumor micrometastases are believed to be the source of disease persistence and...
|
Michael Gnant,
Philippe Clézardin
|
Review article
(In Press Corrected Proof)
|
10 October 2011 |
|
New treatment options for patients with metastatic castration-resistant prostate cancer
DOI: 10.1016/j.ctrv.2011.07.007
Abstract: Chemotherapy for men with metastatic castration-resistant prostate cancer (CRPC) conferred no survival advantage until 2004 when docetaxel was shown to improve survival when compared with mi...
|
Celestia S. Higano
|
Review article
(In Press Corrected Proof)
|
26 September 2011 |
|
The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer
DOI: 10.1016/j.ctrv.2011.09.001
Abstract: Colorectal cancer progression and survival is dependent on complex interactions between the tumour and the host. The pronounced local inflammatory response in and around the tumour is though...
|
C.S.D. Roxburgh,
D.C. McMillan
|
Review article
(In Press Corrected Proof)
|
26 September 2011 |
|
Clinical and future applications of high intensity focused ultrasound in cancer
DOI: 10.1016/j.ctrv.2011.08.004
Abstract: High intensity focused ultrasound (HIFU) or focused ultrasound (FUS) is a promising modality to treat tumors in a complete, non invasive fashion where online image guidance and therapy contr...
|
Osama Al-Bataineh,
Jürgen Jenne,
Peter Huber
|
Review article
(In Press Corrected Proof)
|
19 September 2011 |
|
Pharmacogenetics of anti-estrogen treatment of breast cancer
DOI: 10.1016/j.ctrv.2011.08.003
Abstract: A major effort is underway to select genetic polymorphisms potentially relevant to the clinical efficacy and safety of endocrine treatment of breast cancer. Genetic factors of the host that ...
|
Marzia Del Re,
Angela Michelucci,
Paolo Simi,
Romano Danesi
|
Review article
(In Press Corrected Proof)
|
15 September 2011 |
|
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors
DOI: 10.1016/j.ctrv.2011.07.008
Abstract: The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have become increasingly recognized as having a driving role in the development of malignancy,...
|
Giorgio V. Scagliotti,
Silvia Novello
|
Review article
(In Press Corrected Proof)
|
12 September 2011 |
|
Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice
DOI: 10.1016/j.ctrv.2011.08.002
Abstract: More therapeutic options are now available than ever before for patients with metastatic colorectal cancer (mCRC) and, as such, treatment decisions have become more complex. A multidisciplin...
|
Marc Peeters,
Timothy Price
|
Review article
(In Press Corrected Proof)
|
07 September 2011 |
|
Docetaxel combined with targeted therapies in metastatic breast cancer
DOI: 10.1016/j.ctrv.2011.08.001
Abstract: The treatment of metastatic breast cancer (MBC) is essentially palliative and should be based on hormone therapy or optimized chemotherapy designed to delay disease progression and maximize ...
|
Javier Cortes,
Henri Roché
|
Review article
(In Press Corrected Proof)
|
29 August 2011 |
|
Chemoprevention for breast cancer
DOI: 10.1016/j.ctrv.2011.07.005
Abstract: Despite the progress that has been made in breast cancer diagnosis and treatment, this disease is still a major health problem, being the most frequently diagnosed cancer and the first leadi...
|
I. Bozovic-Spasojevic,
E. Azambuja,
Worta McCaskill-Stevens,
P. Dinh,
F. Cardoso
et al.
|
Review article
(In Press Corrected Proof)
|
19 August 2011 |
|
Electrochemotherapy of chest wall breast cancer recurrence
DOI: 10.1016/j.ctrv.2011.07.006
Abstract: Chest wall breast cancer recurrence after mastectomy is a disease difficult to treat. Its incidence varies between 5% and 30% in different subset of patients. When possible, radical surgical...
|
Gregor Sersa,
Tanja Cufer,
Snezna Marija Paulin,
Maja Cemazar,
Marko Snoj
et al.
|
Review article
(In Press Corrected Proof)
|
19 August 2011 |
|
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML
DOI: 10.1016/j.ctrv.2011.07.004
Abstract: Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding affinity for BCR-ABL compared with imatinib. Nilotinib is approved in patients with imatini...
|
Gianantonio Rosti,
Fausto Castagnetti,
Gabriele Gugliotta,
Francesca Palandri,
Michele Baccarani
et al.
|
Review article
(In Press Corrected Proof)
|
16 August 2011 |
|
A role for maintenance therapy in managing sarcoma
DOI: 10.1016/j.ctrv.2011.07.003
Summary: Despite the use of recommended chemotherapy regimens, patients with metastatic sarcomas have a poor prognosis. To date, the median overall survival for metastatic disease remains less than 18...
|
Isabelle Ray-Coquard,
Axel Le Cesne
|
Review article
(In Press Corrected Proof)
|
16 August 2011 |
|
Cyto-reductive Surgery combined with Hyperthermic Intra-Peritoneal Chemotherapy for Peritoneal Surface Malignancies: Current treatment and results
DOI: 10.1016/j.ctrv.2011.07.001
Abstract: Cyto-reductive Surgery (CS) combined with Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) as loco-regional treatment of Peritoneal Surface Malignancies (PSM) has increasingly gained accep...
|
Antonio Sommariva,
Pierluigi Pilati,
Carlo Riccardo Rossi
|
Review article
(In Press Corrected Proof)
|
02 August 2011 |
|
Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials
DOI: 10.1016/j.ctrv.2011.07.002
Abstract: Background: Health-related quality of life (HRQOL) parameters are often used as end points in phase III trials in advanced breast cancer. The frequency and correlates of significant gains in...
|
Krzysztof Adamowicz,
Jacek Jassem,
Artur Katz,
Everardo D. Saad
|
Review article
(In Press Corrected Proof)
|
02 August 2011 |
|
Skeletal metastasis in renal cell carcinoma: Current and future management options
DOI: 10.1016/j.ctrv.2011.06.011
Abstract: Metastasis to the skeleton is common in advanced renal cancer and leads to debilitating skeletal complications including severe pain, increased fracture rate and spinal cord compression. The...
|
Steven L. Wood,
Janet E. Brown
|
Review article
(In Press Corrected Proof)
|
01 August 2011 |
|
Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review
DOI: 10.1016/j.ctrv.2011.06.009
Abstract: Background: Breast cancer prevention with tamoxifen in high-risk women is limited due to concerns of endometrial cancer and thromboembolism. We report the risk of endometrial cancer, deep ve...
|
Javaid Iqbal,
Ophira M. Ginsburg,
Thiwanka D. Wijeratne,
Anthony Howell,
Gareth Evans,
Ivana Sestak,
Steven A. Narod
et al.
|
Review article
(In Press Corrected Proof)
|
21 July 2011 |
|
Problems involved in the clinical trials for non-small cell lung carcinoma
DOI: 10.1016/j.ctrv.2011.06.001
Abstract: Along with changes in smoking habits, non-small cell lung carcinoma (NSCLC) has come to account for about 90% of all cases of lung cancer. For the treatment of NSCLC, cytocidal antineoplasti...
|
Nagahiro Saijo
|
Review article
(In Press Corrected Proof)
|
20 July 2011 |
|
Open conservation partial laryngectomy for laryngeal cancer: A systematic review of English language literature
DOI: 10.1016/j.ctrv.2011.05.010
Abstract: Background: Different modalities of treatment in early laryngeal cancer lead to equivalent oncological outcomes. Hence this systematic review was undertaken to synthesise the key oncological...
|
Ligy Thomas,
Mike Drinnan,
Basavaiah Natesh,
Hisham Mehanna,
Terry Jones,
Vinidh Paleri
et al.
|
Review article
(In Press Corrected Proof)
|
18 July 2011 |
|
Brain metastases from renal cell carcinoma. Should we change the current standard?
DOI: 10.1016/j.ctrv.2011.06.008
Abstract: Renal cell carcinoma (RCC) is one of the most common sources of brain metastases, with an incidence that varies widely from 4% to 48% according to different studies. In addition, asymptomati...
|
Jordi Remon,
Pilar Lianes,
Susana Martínez
|
Review article
(In Press Corrected Proof)
|
18 July 2011 |
|
Targeting angiogenesis in ovarian cancer
DOI: 10.1016/j.ctrv.2011.06.004
Abstract: Results of standard chemotherapy in ovarian cancer are hampered by the development of drug resistance leading to disease recurrence. This prompted interest in the development of therapies ta...
|
Jordan Schmitt,
Daniela Matei
|
Review article
(In Press Corrected Proof)
|
18 July 2011 |
|
New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
DOI: 10.1016/j.ctrv.2011.06.006
Abstract: Breast cancer is not a single disease. Genetic array tools can define several subtypes. Specific biological processes and distinct gene pathways are associated with prognosis and sensitivity...
|
Giuseppe Curigliano
|
Review article
(In Press Corrected Proof)
|
18 July 2011 |
|
Role of the microenvironment in hepatocellular carcinoma development and progression
DOI: 10.1016/j.ctrv.2011.06.010
Abstract: Hepatocellular carcinoma (HCC) is the most common form of liver cancer throughout the world. The microenvironment of the HCC is composed of non-tumor cells and their stroma, with the stroma ...
|
Sheng-Di Wu,
Yu-Shui Ma,
Ying Fang,
Li-Li Liu,
Da Fu,
Xi-Zhong Shen
et al.
|
Review article
(In Press Corrected Proof)
|
15 July 2011 |
|
Microparticles and their emerging role in cancer multidrug resistance
DOI: 10.1016/j.ctrv.2011.06.005
Abstract: Drug resistance is a major obstacle to the successful treatment of cancer as tumor cells either fail to reduce in size following chemotherapy or the cancer recurs after an initial response. ...
|
J. Gong,
R. Jaiswal,
J.-M. Mathys,
V. Combes,
G.E.R. Grau,
M. Bebawy
et al.
|
Review article
(In Press Corrected Proof)
|
15 July 2011 |
|
The role of PET imaging in overcoming radiobiological challenges in the treatment of advanced head and neck cancer
DOI: 10.1016/j.ctrv.2011.06.003
Abstract: Purpose: Despite the large variety of treatment methods available for the management of advanced head and neck carcinomas, these tumours remain highly challenging due to their aggressiveness...
|
Loredana G. Marcu,
Eva Bezak,
Sanda M. Filip
|
Review article
(In Press Corrected Proof)
|
11 July 2011 |
|
Activity and resistance of trastuzumab according to different clinical settings
DOI: 10.1016/j.ctrv.2011.06.002
Abstract: Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential...
|
Elda Tagliabue,
Manuela Campiglio,
Serenella M. Pupa,
Sylvie Ménard,
Andrea Balsari
et al.
|
Review article
(In Press Corrected Proof)
|
04 July 2011 |
|
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
DOI: 10.1016/j.ctrv.2011.05.009
Highlights: ► Novel targeted agents are being evaluated for advanced NSCLC to improve outcomes. ► These targeted agents are directed toward key components in signalling pathways, such as VEGFR, PDGFR,...
|
C.P. Belani,
G. Goss,
G. Blumenschein
|
Review article
(In Press Corrected Proof)
|
30 June 2011 |
|
Importance of monitoring renal function in patients with cancer
DOI: 10.1016/j.ctrv.2011.05.001
Abstract: Monitoring renal function in patients with solid tumors and hematologic malignancies is vital to the safe administration of therapeutic agents. Renal impairment is frequent in elderly patien...
|
Matti Aapro,
Vincent Launay-Vacher
|
Review article
(In Press Corrected Proof)
|
25 May 2011 |